Lawley Elodie, Baranov Petr, Young Michael
Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, USA.
Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, USA
J Biomater Appl. 2015 Jan;29(6):894-902. doi: 10.1177/0885328214547751. Epub 2014 Aug 20.
Many advances have been made in an attempt to treat retinal degenerative diseases, such as age-related macular degeneration and retinitis pigmentosa. The irreversible loss of photoreceptors is common to both, and currently no restorative clinical treatment exists. It has been shown that retinal progenitor and photoreceptor precursor cell transplantation can rescue the retinal structure and function. Importantly, retinal progenitor cells can be collected from the developing neural retina with further expansion and additional modification in vitro, and the delivery into the degenerative host can be performed as a single-cell suspension injection or as a complex graft transplantation. Previously, we have described several polymer scaffolds for culture and transplantation of retinal progenitor cells of both mouse and human origin. This tissue engineering strategy increases donor cell survival and integration. We have also shown that biodegradable poly(ɛ-caprolactone) induces mature photoreceptor differentiation from human retinal progenitor cells. However, poor adhesive properties limit its use, and therefore it requires additional surface modification. The aim of this work was to study vitronectin-mimicking oligopeptides (Synthemax II-SC) poly(ɛ-caprolactone) films and their effects on human retinal progenitor cell adhesion, proliferation, and differentiation. Here, we show that the incorporation of vitronectin-mimicking oligopeptide into poly(ɛ-caprolactone) leads to dose-dependent increases in cell adhesion; the optimum dose identified as 30 µg/ml. Inhibition of human retinal progenitor cells proliferation was seen on poly(ɛ-caprolactone) and was maintained with the hybrid scaffold. This has been shown to be beneficial for driving cell differentiation. Additionally, we observed equal expression of Nrl, rhodopsin, recoverin, and rod outer membrane 1 after differentiation on the hybrid scaffold as compared to the standard fibronectin coating of poly(ɛ-caprolactone). After transplantation into rd1 retina degenerative mice, human retinal progenitor cells were able to migrate to the outer nuclear layer and survive for three weeks. We conclude that Synthemax II-SC can be incorporated into poly(ɛ-caprolactone) to create a hybrid chemically defined scaffold for clinical application.
为了治疗视网膜退行性疾病,如年龄相关性黄斑变性和色素性视网膜炎,人们已经取得了许多进展。这两种疾病都存在光感受器的不可逆丧失,目前尚无恢复性的临床治疗方法。研究表明,视网膜祖细胞和光感受器前体细胞移植可以挽救视网膜结构和功能。重要的是,视网膜祖细胞可以从发育中的神经视网膜中收集,在体外进一步扩增并进行额外修饰,然后作为单细胞悬液注射或作为复合移植物移植到退行性宿主中。此前,我们已经描述了几种用于培养和移植小鼠和人源视网膜祖细胞的聚合物支架。这种组织工程策略可提高供体细胞的存活率和整合率。我们还表明,可生物降解的聚己内酯可诱导人视网膜祖细胞分化为成熟的光感受器。然而,其较差的粘附性能限制了它的应用,因此需要进行额外的表面修饰。这项工作的目的是研究模拟玻连蛋白的寡肽(Synthemax II-SC)聚己内酯薄膜及其对人视网膜祖细胞粘附、增殖和分化的影响。在此,我们表明将模拟玻连蛋白的寡肽掺入聚己内酯会导致细胞粘附呈剂量依赖性增加;确定的最佳剂量为30μg/ml。在聚己内酯上观察到对人视网膜祖细胞增殖的抑制作用,并且在混合支架上这种抑制作用得以维持。这已被证明有利于驱动细胞分化。此外,与聚己内酯的标准纤连蛋白涂层相比,我们观察到在混合支架上分化后Nrl、视紫红质、恢复蛋白和视杆外膜1的表达相当。将人视网膜祖细胞移植到rd1视网膜退行性小鼠体内后,它们能够迁移到外核层并存活三周。我们得出结论,Synthemax II-SC可以掺入聚己内酯中,以创建一种用于临床应用的混合化学定义支架。